

MTI APPOINTS DR. DAVID CHANG AS NEW CEO

Metabolomic Technologies Inc.(MTI) announced that it has appointed David Chang as Chief Executive Officer. Dr. Chang replaced Reg Joseph as CEO on May 1, 2017. Mr. Joseph has been on leave to Alberta Innovates since 2016. Dr. Richard Fedorak remains as President and Chief Medical Officer of MTI.

“David is going to take MTI to the next level”, says Joseph. “His leadership and vision for innovation and improved efficiency to drive growth, make him an extraordinary fit for MTI.”

As Chief Operating Officer for Metabolomic Technologies Inc. since 2016, Dr. Chang has helped establish MTI as a respected, award-winning innovator. He oversaw all company operations, including the development of MTI’s flagship product, PolypDx™, from the research lab to market with the signing of a multi-million dollar exclusive licensing and distribution agreement in 12 U.S. states.



Dr. Chang has over 15 years of experience managing SMEs, bringing products to market in the emerging field of metabolomics. He has applied his expertise in signal processing, multivariate statistics and modelling to leading-edge biomarker diagnostic applications.

Before joining Metabolomic Technologies Inc. in 2015, Dr. Chang was employed by Chenomx Inc., where he developed and managed significant business operations.

David Chang completed his Bachelors and Masters of Applied Science at the University of Waterloo and a PhD in Chemical and Materials Engineering at the University of Alberta, where he was first involved in the early discoveries of using Nuclear Magnetic Resonance for metabolomics. David has made Edmonton, Canada his home since 2001, where he is actively involved in the sports of curling and cycling.